Milestone Pharmaceuticals (MIST) Q1 2026 earnings review
Commercial Era Begins: CARDAMYST Launch Drives Spending and Early Revenue
Milestone reported its first-ever product revenue ($0.2M) following the mid-February US launch of CARDAMYST for PSVT. While revenue is nascent, the critical update is payer access: securing Express Scripts national formulary coverage addresses the biggest hurdle to commercial adoption. The transition to a commercial organization caused the net loss to accelerate to $26.1M as commercial expenses surged 52% YoY to $15.8M. Backed by a fortified $184.2M cash position, the company has runway into late 2027 to execute the launch and initiate the label-expanding AFib-RVR Phase 3 trial.
🐂 Bull Case
Adding CARDAMYST to the Express Scripts national formulary in March is a massive early win. With >25% of commercial lives now covered, the risk of early prescription abandonment (previously flagged by management as >50% pre-coverage) is substantially reduced.
Achieving 600 filled scripts across 400 unique prescribers through April shows that demand is widespread across the target market, rather than being concentrated among a few highly active physicians.
🐻 Bear Case
Commercial expenses hit $15.8M in a single quarter to support a 60-person sales force and marketing efforts. The cost of commercialization will heavily weigh on the bottom line before meaningful revenue materializes.
While commercial coverage is expanding, Medicare patients—representing roughly 50% of the target population—are not expected to have formulary access until 2027, capping near-term volume potential.
⚖️ Verdict: ⚪
Cautiously Optimistic. The Express Scripts formulary win effectively de-risks the early launch phase, proving payers see value in the first new PSVT drug in 30 years. However, the steep acceleration in commercial spending requires execution to be flawless to avoid a future cash crunch.
Key Themes
Express Scripts Catalyzes Access
In the prior quarter, management warned that standard payer blocks would act as a 'natural dampening' on early prescription fills. The March 27 addition to Express Scripts’ national commercial formularies directly mitigates this concern, expanding coverage to over 25% of U.S. commercial lives within weeks of launch. This accelerated access timeline is a primary driver for future volume growth.
Indication Expansion: AFib-RVR Trial Initiated
Milestone has officially initiated its Phase 3 registrational program for AFib-RVR, with patient enrollment scheduled to begin in H2 2026. This is a crucial technological milestone: utilizing the same self-administered nasal spray delivery mechanism, but targeting a separate, massive cardiovascular market. Success here would significantly expand the total addressable market beyond PSVT.
Commercial Expense Acceleration
The financial reality of launching a novel drug is starkly visible. Commercial expenses accelerated from $8.2M in 25Q4 to $15.8M in 26Q1, dwarfing the $0.2M in initial revenue. While management highlights a strong balance sheet, a $23.6M quarterly operating loss means the $184M cash pile will drain rapidly if sales do not scale exponentially to meet the fixed costs of the 60-person national sales force.
Ex-US Partnerships Validate Asset
Global expansion is moving forward without draining US capital. Everest Medicines acquired rights for Greater China (where an NDA is under review), and the EMA has accepted the MAA for European review (decision expected H1 2027). These external validations provide potential future non-dilutive milestone and royalty streams.
Unproven Gross-to-Net Dynamics
Securing Express Scripts coverage so rapidly is impressive, but it historically requires heavy manufacturer rebates. Coupled with the company's aggressive patient assistance platform and co-pay programs to cover the other 75% of commercial lives, actual realized price per script (gross-to-net) remains an unknown risk factor that could compress future margins.
Macro Environment Pressures Healthcare Utilization
Management notes potential risks from deteriorating market conditions and inflation affecting healthcare utilization. For a self-administered rescue therapy like CARDAMYST, out-of-pocket costs for commercially insured patients could inhibit refill rates if discretionary spending remains pressured by macro factors.
Other KPIs
Accelerating. Up significantly from $106.0M at the end of 2025. This surge was primarily driven by the previously announced $75M royalty financing from RTW Investments and ATM usage, fortifying the balance sheet exactly when launch expenses peak.
Decelerating. R&D spending dropped from $5.0M in the prior year period. This reflects the transition out of the regulatory review phase for the PSVT indication. Expect this metric to reverse and accelerate again in H2 2026 as the AFib-RVR Phase 3 trial begins patient enrollment.
Guidance
Stable. The company reiterated its expectation that current liquidity is sufficient to fund operating expenses and capital expenditures into the second half of 2027. This crucially covers the initiation of the Phase 3 AFib-RVR trial and over a year of commercial launch data.
Management provided a specific timeline for clinical advancement, moving from the current site onboarding phase to active enrollment in the second half of 2026.
Stable. The EMA is currently reviewing the MAA based on the same global clinical data package used for US approval. A decision is expected in the first half of 2027.
Key Questions
Gross-to-Net Dynamics
With the Express Scripts formulary win achieved so early in the launch, what level of rebates or concessions were required, and how should we model the gross-to-net discount for CARDAMYST in its first 12-18 months?
Patient Assistance Cost Burden
Of the approximately 600 scripts filled through April, what percentage were heavily subsidized by Milestone's patient assistance and co-pay bridge programs versus standard commercial insurance fulfillment?
Refill Rates and Utilization
For the early cohort of patients who received CARDAMYST in February and March, what are the early indicators of real-world usage and refill behavior once a patient experiences a PSVT episode?
AFib-RVR Trial Design
As site onboarding begins for the Phase 3 AFib-RVR trial, what is the expected enrollment size, and when do you anticipate providing guidance on a top-line data readout?